Sanofi SNY announced positive results of a new post-hoc analysis of data from a phase III trial that evaluated its investigational candidate, iGlarLixi, a titratable fixed-ratio combination of insulin ...

COPENHAGEN, Denmark, Dec. 4, 2017 /PRNewswire/ -- New findings from an indirect comparison between Xultophy ® and IGlarLixi published in the Journal of Medical Economics show that treatment with ...

Zealand Pharma announced that Sanofi has submitted to the FDA updated data for iGlarLixi (insulin glargine and lixisenatide) as part of its New Drug Application (NDA) for the treatment of adults with ...

At month 6, the least-squares mean change in A1c levels from baseline was −1.4% (95% CI, −1.5 to −1.3). By month 12, both fasting and postprandial glucose levels decreased following treatment with ...

The FDA’s diabetes experts provided their second endorsement for a treatment duo in two days, voting 12 to 2 to back Sanofi’s marketing application for a combination of its franchise blockbuster ...

Treatment with iGlarLixi resulted in a lower rate of gastrointestinal (GI) adverse events vs. Lixi, according to findings from a post-hoc analysis. This article is written live from the American ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Handelsman and colleagues conducted a post hoc analysis ...

Sanofi is highlighting new data for its IGlarLixi combination drug for diabetes showing it is more effective at controlling mealtime blood glucose than its Lantus blockbuster. The French pharma group ...

* Type 2 diabetes patients treated with iGlarLixi (formerly LixiLan) had significantly greater reductions in blood glucose (HbA1c) versus treatment with either lixisenatide or Lantus * Treatment with ...

Nevertheless, we can speculate as to what’s going on here, and that it may in fact be synergy. Since GLP-1 drugs are glucose-dependent and cause the pancreas to produce insulin in a glucose-dependent ...

When managing type 2 diabetes, the once-daily iGlarLixi (Soliqua) edged out the twice-daily premix insulin analog BIAsp 30, according to the SoliMix trial. The 26-week, open-label trial included ...

New findings from an indirect comparison between Xultophy and IGlarLixi published in the Journal of Medical Economics show that treatment with Xultophy (insulin degludec/liraglutide) provides ...